Linked Life Data

19300959

Source:http://linkedlifedata.com/resource/pubmed/id/19300959

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2009-3-20
pubmed:abstractText
Following promising results in animal studies showing that immunosuppression and consecutive allogeneic bone marrow transplantation has the potential to significantly reduce autoimmunity, emerging data is supporting a benefit in patients with multiple sclerosis (MS) and other autoimmune disorders not responding to approved therapies. Until today, results on over 400 cases have been reported by the European Blood and Marrow Transplantation Group (EBMT), many of them with a favorable outcome. However, results of randomized, controlled clinical trials are missing. Furthermore, with upcoming new treatment compounds that to some extent act via lymphoablative properties, it remains essential to better select those patients who might profit most from stem cell therapy based on a justifiable benefit-to-risk ratio.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0340-5354
pubmed:author
pubmed:issnType
Print
pubmed:volume
255 Suppl 6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
43-7
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Stem cell transplantation in multiple sclerosis.
pubmed:affiliation
Institute of Neuroimmunology and Multiple Sclerosis Research (INiMS), Center of Molecular Neurobiology, Falkenried 3, 20246 Hamburg, Germany. s.schippling@uke.uni-hamburg.de
pubmed:publicationType
Journal Article, Review